medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 3

<< Back Next >>

Ann Hepatol 2015; 14 (3)

HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?

Persico M, Coppola N, Rosato V, Abenavoli L, Masarone M, De Luna A

Language: English
References: 27
Page: 325-332
PDF size: 115.28 Kb.


ABSTRACT

Background and rationale of the study. Hepatitis C infection is very common among injection drug users(IDUs). In clinical practice there is reluctance to treat IDUs, because considered difficult-to-treat. Aim of this study was to evaluate the response to antiviral treatment in IDUs compared to non-IDUs. Main results. In this observational retrospective study, 204 non cirrhotic patients(112 IDUs, 92 non-IDUs) with chronic hepatitis C, treated with PEG-IFN and ribavirin in a tertiary centre for IDUs of Southern Italy from 2008 to 2011 were analyzed. Age, sex, genotype, steatosis, response to previous therapy, rapid(RVR), early(EVR), end-of-treatment(ETR), sustained(SVR) virological response were evaluated. IDUs were mainly young and males, with prevalence of genotype 3. A higher SVR rate in IDUs group compared to non-IDUs only in PerProtocol(PP) analysis (90% vs. 78,9% ;p = 0.04). On the contrary, in IntentionToTreat(ITT) analysis, no significant difference was relieved. A higher SVR rate at ITT analyses in naïve non-IDUs patients was found (76,13% vs. 90%, p = 0.021), but at PP analysis wasn’t confirmed. Treatment was well tolerated; a higher dropout rate was reported in IDUs (24 patients) compared to non-IDUs (2 patients). In order to exclude the effect of viral genotypes on SVR a genotype matched statistical analysis was done and no difference was found. Conclusions. IDUs naïve patients, due to young age and high prevalence of genotype 3, appear good candidates to dual antiviral therapy with high SVR rates. Dropout is the main non-response cause among these subjects, but through an optimal monitoring program with a multidisciplinary setting, their “difficult to treat” characteristics can be overcome.


REFERENCES

  1. Zanini B, Lanzini A. Antiviral treatment for chronic hepatitis C in illicit drug users: a systematic review. Antivir Ther 2009; 14: 467-79.

  2. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.

  3. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52: 889-900.

  4. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, et al. A sustained virologic response is durable in patients with chronic hepatitis C with peginterferon alfa-2a and ribavirin. Gastroenterol 2010; 139: 1593-601.

  5. Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic Hepatitis C: a meta-analysis. BMC Infect Dis 2012; 12: 357.

  6. de Bruijne J, Buster EHCJ, Gelderblom HC, Brouwer JT, de Knegt RJ, van Erpecum KJ, Schalm SW, et al. Treatment of chronic hepatitis C virus infection – Dutch national guidelines. Netherlands J Med 2008; 66: 311-22.

  7. McCaughan GW. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22: 615-63.

  8. Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PlosOne 2014. In Press.

  9. Lawitz, E, Mangia A, Wyles D, Rodriquez-Torres M, Hassanein T, Gordon SC, Schultz M, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.

  10. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez- Torres M, Sulkowski MS, Shiffman ML, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.

  11. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-73.

  12. Cooper CL, Mills EJ. Therapeutic challenges in hepatitis Cinfected injection drug using patients. Harm Reduction J 2006; 3: 31.

  13. Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, Cheever LW, et al. Overcoming barriers to prevention, care and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005; 40: S276-S285.

  14. Postma MJ, Wiessing LG, Jager JC. Pharmaco-economics of drug addiction: estimating the costs of hepatitis C virus, hepatitis B virus, and human immunodeficiency virus infection among injecting drug users in Member States of the European Union. United Nations Bulletin of Narcotics 2001; 53: 79-89.

  15. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000; 284: 3043-5.

  16. Germer JJ, Harmsen WS, Mandrekar JN, Mitchell PS, Yao JD. Evaluation of the COBAS TaqMan HCV test with automated sample processing using the MagNA pure LC instrument. J Clin Microbiol 2005; 43: 293-8.

  17. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339: 237-8.

  18. Viazov S, Zibert A, Ramakrishnan K, Widell A, Cavicchini A, Schreier E, Roggendorf M. Typing of hepatitis C virus isolates by DNA enzyme immunoassay. J Virol Methods 1994; 48: 81-92.

  19. Bruggmann P, Falcato L, Dober S, Helbling B, Keiser O, Negro F, Meili D, et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat 2008; 15: 747-52.

  20. Dore GJ, Hellard M, Matthews G, Grebely J, Haber PS, Petoumenos K, Yeung B, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138: 123.

  21. Zanini B, Covolo L, Donato F, Lanzini A. Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies. Clin Ther 2010; 32: 2139-59.

  22. Gigi E, Sinakos E, Sykia A, Androulakis G, Tanis C, Stayridou V, Tsirogianni E, et al. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users. J Addict Med 2013; 7: 52-7

  23. Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, Mehta S, et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatol 2006; 43: 788-95.

  24. Masarone M, Persico M. Antiviral therapy: why does it fail in HCV-related chronic hepatitis? Expert Rev Anti Infect Ther 2011; 9: 535-43.

  25. Gazdag G, Horvath G, Szabo O, Ungvari GS. Difficulties with interferon treatment in former intravenous drug users. Braz J Infect Dis 2011; 15: 163-6.

  26. Seal KH, Currie SL, Shen H, Anand BS, Bini EJ, Brau N, Jeffers L, et al. Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drog us matter? J Clin Gastroenterol 2007; 41: 199-205.

  27. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, et al. Adherence and Mental Side Effects During Hepatitis C Treatment With Interferon Alfa and Ribavirin in Psychiatric Risk Groups. Hepatology 2003; 37: 443-51.




2020     |     www.medigraphic.com